经济观察报记者张铃 1月30日，诺和诺德宣布，全球高级副总裁兼大中国区总裁周霞萍决定离开诺和诺德，最后工作日为3月 31日。 周霞萍毕业于上海医科大学，1988年进入中山医院做医生。1994年，她转行到制药行业，最初在华瑞制 药(中国和瑞典的第一家合资药企)担任品牌助理，3年后加入礼来，此后在礼来工作了20年，其中11年 在美国、马来西亚等海外市场任职，最终成为礼来中国高级副总裁兼抗肿瘤产品及跨生化产品中国负责 人。 诺和诺德同时宣布，任命蔡琰为大中国区总裁。蔡琰毕业于中山医科大学，并获得哥本哈根大学博士学 位。她在诺和诺德工作超23年，曾在北京建立区域临床开发中心、推动区域临床开发中心新架构在国际 运营部的落地。 诺和诺德是一家有103年历史的跨国制药巨头，最初靠胰岛素产品起家，百年来也一直在糖尿病领域有 所建树。近几年，其以横空出世的减肥药司美格鲁肽引领着新一轮全球范围内火热的GLP-1靶点竞赛。 不过，近一年，诺和诺德被业绩增速放缓、裁员和高管变动的阴云笼罩。 诺和诺德2025年前三季度财报显示，全球总营收为345亿美元，同比增长15%；中国市场收入22亿美 元，同比增长8%，增速低于全球水平。其中，核 ...

Core Insights - The new National Medical Insurance Drug List and Commercial Health Insurance Innovative Drug List will be implemented in Wuhan starting January 1, 2026, focusing on "clinical urgency, affordability, and diverse coverage" [1] - The updated list includes 114 new drugs, with a significant emphasis on oncology and rare diseases, complementing the basic medical insurance coverage [2][5] Summary by Sections New Drug Inclusion - The revised National Medical Insurance Drug List now includes a total of 3,253 drugs, with 1,857 Western medicines and 1,396 traditional Chinese medicines [2] - Among the 114 newly added drugs, 50 are classified as innovative drugs, achieving a high inclusion success rate of 88%, with over 90% being newly approved in the last five years [2] Price Reductions - The average price reduction for the newly included drugs is 63%, with some high-profile drugs seeing reductions exceeding 70% [3] - For instance, the monthly cost of the drug Tirzepatide, previously between 1,700 to 2,000 yuan, is now reduced to 324.1 yuan for the 2.5 mg dosage and 936.7 yuan for the 10 mg dosage, significantly lowering the annual burden for patients in Wuhan by over 15,000 yuan [3] Commercial Health Insurance Innovations - The first edition of the Commercial Health Insurance Innovative Drug List includes 19 high-value innovative drugs, addressing gaps in basic medical insurance coverage [5] - This list features CAR-T cell therapy drugs and treatments for rare diseases, with some therapies costing over 400,000 yuan annually [5] Dual-Channel System Expansion - The dual-channel drug list has expanded to 621 drugs, significantly increasing from the previous version [7] - This includes 321 drugs for targeted therapies, rare diseases, infectious diseases, and mental health, with specific policies for outpatient special diseases to ensure precise benefit delivery [7] Streamlined Processes - All designated retail pharmacies in Wuhan have implemented electronic prescription systems, allowing patients to choose between hospital pharmacies and designated stores for immediate reimbursement [7] - The new system aims to enhance efficiency and reduce patient wait times, promoting a more convenient healthcare experience [7] Collaboration and Communication - Wuhan is establishing a continuous communication platform between pharmaceutical companies and medical institutions to facilitate the understanding of new drug characteristics and supply [8] - By February 2026, all medical institutions are required to adjust their drug procurement processes to ensure the availability of newly negotiated drugs [8]

Core Insights - Novo Nordisk has submitted applications to the FDA for the approval of icodec insulin for the treatment of type 2 diabetes and Mim8 for the treatment of hemophilia A [1] Group 1: Icodec Insulin - Icodec insulin is a long-acting insulin formulation designed based on oral insulin OI338, with a half-life of 196 hours [2] - The design modifications include replacing an 18C fatty acid with a 20C fatty acid to enhance binding affinity to human serum albumin, and substituting Tyr with His at position 16 of the B chain to reduce affinity to human insulin receptors [2] - The initial BLA submission in April 2023 included indications for both type 1 and type 2 diabetes, but the FDA advisory committee found insufficient data for type 1 diabetes, leading to a narrowed indication for type 2 diabetes in the resubmission [2] Group 2: Mim8 - Mim8 is a bispecific antibody developed using Genmab's DuoBody technology, designed to mimic the action of coagulation factor VIIIa (FVIIIa) and bridge factors IXa (FIXa) and X (FX) [3] - It exhibits approximately 15 times the coagulation activity compared to emicizumab [3] - Hemophilia A, affecting around 80%-85% of the estimated 1.125 million hemophilia patients globally, is caused by a deficiency or defect in FVIII [3] Group 3: Hemophilia Treatment Landscape - There are currently 46 approved hemophilia drugs globally, with only 8 being non-factor therapies [4] - Among these, several drugs have been approved specifically for hemophilia A patients, including concizumab, valoctocogene roxaparvovec, emicizumab, marstacimab, and fitusiran [4]